Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
Adult
Aged
Aged, 80 and over
Chemoradiotherapy, Adjuvant
DNA Mismatch Repair
DNA Polymerase II
/ genetics
DNA-Binding Proteins
/ genetics
Endometrial Neoplasms
/ drug therapy
Female
Humans
Immunohistochemistry
Middle Aged
Paraffin Embedding
Poly-ADP-Ribose Binding Proteins
/ genetics
Prognosis
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic
Tumor Suppressor Protein p53
/ genetics
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
10 10 2020
10 10 2020
Historique:
pubmed:
5
8
2020
medline:
5
3
2021
entrez:
5
8
2020
Statut:
ppublish
Résumé
The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endometrial cancer (EC). Because The Cancer Genome Atlas defined an EC molecular classification with strong prognostic value, we investigated prognosis and impact of chemotherapy for each molecular subgroup using tissue samples from PORTEC-3 trial participants. Paraffin-embedded tissues of 423 consenting patients were collected. Immunohistochemistry for p53 and mismatch repair (MMR) proteins, and DNA sequencing for Molecular analysis was successful in 410 high-risk EC (97%), identifying the 4 subgroups: p53abn EC (n = 93; 23%), Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with
Identifiants
pubmed: 32749941
doi: 10.1200/JCO.20.00549
pmc: PMC7527156
doi:
Substances chimiques
DNA-Binding Proteins
0
Poly-ADP-Ribose Binding Proteins
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
DNA Polymerase II
EC 2.7.7.7
POLE protein, human
EC 2.7.7.7
Banques de données
ISRCTN
['ISRCTN14387080']
ClinicalTrials.gov
['NCT00411138']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3388-3397Subventions
Organisme : Cancer Research UK
ID : 8659
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR-CS-012-009
Pays : United Kingdom
Références
Histopathology. 2020 Jan;76(1):52-63
pubmed: 31846532
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Lancet Oncol. 2016 Aug;17(8):1114-1126
pubmed: 27397040
Clin Cancer Res. 2019 Dec 15;25(24):7517-7526
pubmed: 31492746
J Pathol. 2020 Mar;250(3):312-322
pubmed: 31829447
Lancet Oncol. 2018 Mar;19(3):295-309
pubmed: 29449189
Exp Mol Pathol. 2013 Feb;94(1):121-5
pubmed: 22750048
Am J Surg Pathol. 2019 May;43(5):591-600
pubmed: 30864976
J Pathol. 2020 Mar;250(3):336-345
pubmed: 31829441
Ann Oncol. 2017 Jan 1;28(1):96-102
pubmed: 27742654
J Clin Oncol. 2018 Jul 10;36(20):2044-2051
pubmed: 29584549
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
J Pathol. 2020 Mar;250(3):323-335
pubmed: 31829442
Gynecol Oncol. 2019 Jul;154(1):124-130
pubmed: 31103324
Arch Pathol Lab Med. 2014 Mar;138(3):343-50
pubmed: 24576030
Ann Oncol. 2018 Feb 1;29(2):424-430
pubmed: 29190319
Lancet Oncol. 2019 Sep;20(9):1273-1285
pubmed: 31345626
Am J Surg Pathol. 2013 Jun;37(6):874-81
pubmed: 23629444
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
J Clin Oncol. 2019 Jul 20;37(21):1810-1818
pubmed: 30995174
Clin Cancer Res. 2018 Jul 1;24(13):3197-3203
pubmed: 29559562
Ann Oncol. 2017 Jul 1;28(suppl_4):iv153-iv156
pubmed: 28881926
Clin Cancer Res. 2016 Aug 15;22(16):4215-24
pubmed: 27006490
Clin Cancer Res. 2016 Jun 15;22(12):2865-73
pubmed: 26763250
Br J Cancer. 2015 Mar 3;112(5):793-801
pubmed: 25675149
Mod Pathol. 2017 Jul;30(7):1032-1041
pubmed: 28281553
J Immunother Cancer. 2018 Jun 4;6(1):46
pubmed: 29866197
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Clin Cancer Res. 2019 Feb 1;25(3):1087-1097
pubmed: 30413523
Nat Rev Cancer. 2016 Feb;16(2):71-81
pubmed: 26822575
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027